More recently, the combination of oxaliplatin and irinotecan has

More recently, the combination of oxaliplatin and irinotecan has also been explored. In a randomized phase III study by Falcone et al., patients received either 48-h infusional 5-FU (3,200 mg/m2), LV (200 mg/m2), oxaliplatin (85 mg/m2), and irinotecan (165 mg/m2) (FOLFOXIRI) vs. FOLFIRI (20). The FOLFOXIRI regimen was associated with significantly increased ORR (66% vs. 41%, respectively), PFS (9.8 vs. 6.9 months, respectively), and OS (median, 22.6 vs. 16.7 months, respectively). Even though FOLFOXIRI was also Inhibitors,research,lifescience,medical associated with higher

levels of Grade 2/3 toxicities, the FOLFOXIRI regimen has been accepted as another first-line therapeutic option for patients with mCRC. Emergence of targeted therapies for metastatic colorectal cancer Although outcomes Inhibitors,research,lifescience,medical have improved with advances in systemic chemotherapy for

mCRC, potent small molecules and selleckbio antibodies targeting specific proteins have also been developed over the past decade and have further improved the efficacy of standard chemotherapy regimens. The first of these aptly named “targeted agents” to show benefit as first-line therapy for patients with mCRC was bevacizumab, a recombinant humanized monoclonal IgG1 antibody targeting vascular endothelial growth screening library factor Inhibitors,research,lifescience,medical (VEGF). Hurwitz et al. showed that patients with mCRC who received bevacizumab + IFL had significantly better ORR (44.8% vs. 34.8%, respectively), PFS (10.6 vs. 6.2 months, respectively), and OS (median, 20.3 vs. 15.6 months, respectively) compared to IFL alone (21). By virtue of its mechanism of action as an anti-angiogenesis Inhibitors,research,lifescience,medical agent, bevacizumab must be used with caution in both medical and surgical

patients because of known adverse events including gastrointestinal perforation, hemorrhage, and impaired wound healing (22,23). The second well-established Inhibitors,research,lifescience,medical molecular target in mCRC is epidermal growth factor receptor (EGFR), which is overexpressed in nearly 85% of colorectal cancers (24,25). Cetuximab, a chimeric IgG1 monoclonal antibody directed against the external surface of EGFR, was first evaluated in combination with chemotherapy in patients who were refractory to irinotecan and also as a single agent in patients intolerant to standard chemotherapy (26-29). These randomized, phase II and phase III trials showed improved PFS without differences Cilengitide in OS (29). More recently, Van Cutsem et al., demonstrated an OS benefit with cetuximab when the cohort was limited to patients with wild-type KRAS in their cancers (30). A 2nd EGFR-targeted antibody, panitumumab is a fully humanized IgG2 monoclonal antibody that was initially approved by the FDA as a third-line treatment for mCRC in 2007 (31). The PRIME trial utilized a combination of panitumumab + FOLFOX4 in patients with wild-type KRAS that revealed improved PFS but a non-significant increase in OS compared to FOLFOX4 alone. Currently, panitumumab is FDA-approved for use in patients with refractory mCRC (32).

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>